CYP2D1 polymorphism in methamphetamine-treated rats: Genetic differences in neonatal mortality and effects on spatial learning and acoustic startle

Neurotoxicology and Teratology

Volumn 20, Issue 3, 1998, Pages 265-273

  Vorhees, Charles V ^a,c   Reed, Tracy M ^a   Schilling, Mary A ^a,d   Fisher, J Edward ^a,e   Moran, Mary S ^a   Cappon, Gregg D ^a   Nebert, Daniel W ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^d Department of Biology ^*  (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

ACI inbred rat strain; Black Agouti inbred rat strain; CYP2DI; Cytochrome P450; Debrisoquine polymorphism; Development; Morris maze Methamphetamine; Sprague Dawley rat strain

Indexed keywords

CYTOCHROME P450 ISOENZYME; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; LATENT PERIOD; MAZE TEST; NEUROTOXICITY; NEWBORN; NEWBORN MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL ORIENTATION; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; SWIMMING;

ACOUSTIC STIMULATION; ALCOHOL OXIDOREDUCTASES; ANIMALS; ANIMALS, NEWBORN; ANIMALS, SUCKLING; ARYL HYDROCARBON HYDROXYLASES; BODY WEIGHT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; FEMALE; MAZE LEARNING; METHAMPHETAMINE; PHENOTYPE; POLYMORPHISM, GENETIC; RATS; RATS, INBRED ACI; RATS, SPRAGUE-DAWLEY; STARTLE REACTION; SURVIVAL RATE;

EID: 0031748025     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(97)00129-3     Document Type: Article

References (29)

1. Al-Dabbagh, S. G.; Idle, J. R.; Smith, R. L.: Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol. 33:161-164; 1981.
2. Baba, T.; Yamada, H.; Oguri, K.; Yoshimura, H.: Participation of cytochrome P-450 isozymes in N-demethylation, N-hydroxylation and aromatic hydroxylation of methamphetamine. Xenobiotica 18:475-484; 1988.
3. Bayer, S. A.; Altman, J.; Russo, R. J.; Zhang, X.: Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14:83-144; 1993.
4. Boobis, A. R.; Seddon, C. E.; Davies, D. S.: Bufuralol 1′-hydroxylase activity of the rat: Strain differences and the effects of inhibitors. Biochem. Pharmacol. 35:2961-2965; 1986.
5. Cho, A. K.: Ice: A new dosage form of an old drug. Science 249:631-634; 1990.
6. Colado, M. I.; Williams, J. L.; Green, A. R.: The hyperthermic and neurotoxic effects of 'ecstasy' (MDMA) and 3,4-methylene-dioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115:1281-1289; 1995.
7. Derlet, R. W.; Heischober, B.: Methamphetamine: Stimulant of the 1990s? West. J. Med. 153:625-628; 1990.
8. Dixon, S. D.: Effects of transplacental exposure to cocaine and methamphetamine on the neonate. West. J. Med. 150:436-442; 1989.
9. Dixon, S. D.; Bejar, R.: Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J. Pediatr. 115:770-778; 1989.
10. Eichelbaum, M.: Polymorphic drug oxidation in humans. Fed. Proc. 43:2298-2302; 1984.
11. Gallagher, M.; Burwell, R.; Burchinal, M.: Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze. Behav. Neurosci. 107:618-626; 1993.
12. Gonzalez, F. J.; Meyer, U. A.: Molecular genetics of the debrisoquin-sparteine polymorphism. Clin. Pharmacol. Ther. 50:233-238; 1991.
13. Holson, R. R.; Pearce, B.: Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol. Teratol. 14:221-228; 1992.
14. Idle, J. R.; Smith, R. L.: Polymorphisms of oxidation at carbon centers of drug and their clinical significance. Drug Metab. Rev. 9:301-317; 1979.
15. Little, B. B.; Snell, L. M.; Gilstrap, L. C.: Methamphetamine abuse during pregnancy: Outcome and fetal effects. Obstet. Gynecol. 72:541-544; 1988.
16. Matsunaga, E.; Zanger, U. M.; Hardwick, J. P.; Gelboin, H. V.; Meyer, U. A.; Gonzalez, F. J.: The CYP2D gene subfamily: Analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28:7349-7355; 1989.
17. Morris, R.: Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11:47-60; 1984.
18. Morris, R. G. M.: Spatial localization does not require the presence of local cues. Learn. Motiv. 12:239-260; 1981.
19. Muralidharan, G.; Hawes, E. M.; McKay, G.; Korchinski, E. D.; Midha, K. K.: Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Eur. J. Clin. Pharmacol. 41:471-474; 1991.
20. Muralidharan, G.; Hawes, E. M.; McKay, G.; Midha, K. K.: Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Xenobiotica 21:1441-1450; 1991.
21. Muralidharan, G.; Midha, K. K.; McKay, G.; Hawes, E. M.; Inaba, T.: Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica 19:189-197; 1989.
22. Nebert, D. W.: Identification of genetic differences in drug metabolism: Prediction of individual risk of toxicity or cancer. Hepatology 14:398-401; 1991.
23. Nebert, D. W.; McKinnon, R. A.; Puga, A.: Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer. DNA Cell Biol. 15:273-280; 1996.
24. Oro, A. S.; Dixon, S. D.: Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates. J. Pediatr. 111:571-578; 1987.
25. Tyndale, R. F.; Sunahara, R.; Inaba, T.; Kalow, W.; Gonzalez, F. J.; Niznik, B.: Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol. 40:63-68; 1991.
26. Vorhees, C. V.; Ahrens, K. G.; Acuff-Smith, K. D.; Schilling, M. A.; Fisher, J. E.: Methamphetamine exposure during early postnatal development in rats: I. Acoustic startle augmentation and spatial learning deficits. Psychopharmacology (Berlin) 114:392-401; 1994.
27. Vorhees, C. V.; Ahrens, K. G.; Acuff-Smith, K. D.; Schilling, M. A.; Fisher, J. E.: Methamphetamine exposure during early postnatal development in rats: II. Hypoactivity and altered responses to pharmacological challenge. Psychopharmacology (Berlin) 114: 402-408; 1994.
28. Vorhees, C. V.; Reed, T. M.; Schilling, M. S.; Acuff-Smith, K. D.; Fisher, J. E.; Moran, M. S.: Neonatal methamphetamine-induced long-term startle facilitation in rats as a function of prepulse stimulus intensity. Neurotoxicol. Teratol. 18:135-139; 1996.
29. Yamamoto, T.; Takano, R.; Egashira, T.; Yamanaka, Y.: Metabolism of methamphetamine, amphetamine and p-hydroxymethamphetamine by rat-liver microsomal preparations in vitro. Xenobiotica 14:867-875; 1984.